Loading…
ANG Lifesciences India (BSE 540694)₹36.93−2.97%Pharmaceuticals
In the Jun 2026 quarter (consolidated), ANG Lifesciences India reported sales of ₹15.25 Cr, down 37.8% from Jun 2025, and net profit of −₹4.25 Cr. For the year to Mar 2026, sales were ₹92.71 Cr and net profit −₹11.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.17 | 18.48 | 37.71 | 18.37 | 32.76 | 24.65 | 16.76 | 24.53 | 25.98 | 18.66 | 23.43 | 15.25 |
| Expenses | 31.64 | 20.50 | 34.54 | 20.14 | 30.66 | 26.93 | 17.56 | 23.98 | 26.01 | 21.46 | 20.85 | 17.28 |
| Operating Profit | 1.65 | −1.90 | 3.35 | −1.70 | 2.27 | −2.14 | −0.69 | 0.64 | 0.07 | −2.67 | 2.67 | −1.94 |
| OPM % | 5.0% | −10.4% | 8.9% | −9.3% | 6.9% | −8.7% | −4.2% | 2.6% | 0.3% | −14.4% | 11.4% | −12.8% |
| Other Income | 0.21 | −0.02 | −1.54 | 1.27 | 0.34 | −0.26 | 0.64 | 0.08 | 0.11 | 0.15 | 0.16 | 0.10 |
| Interest | 2.28 | 2.52 | 3.85 | 2.09 | 2.17 | 1.99 | 2.43 | 1.95 | 1.90 | 1.92 | 2.19 | 2.23 |
| Depreciation | 2.21 | 1.90 | 2.04 | 1.62 | 1.73 | 1.95 | 1.41 | 1.52 | 1.51 | 1.50 | 1.76 | 1.49 |
| Profit before tax | −2.64 | −6.35 | −4.09 | −4.13 | −1.28 | −6.39 | −3.90 | −2.72 | −3.22 | −5.95 | −1.09 | −5.59 |
| Tax % | −12.1% | −6.9% | −10.5% | −25.8% | 62.1% | −18.6% | −47.0% | −26.7% | −8.3% | −20.2% | 25.6% | −24.0% |
| Exceptional items | 0.00 | 0.00 | −2.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | −2.31 | −5.94 | −3.64 | −3.08 | −2.10 | −5.20 | −2.07 | −2.02 | −2.94 | −4.74 | −1.39 | −4.25 |
| EPS (Rs) | −1.79 | −4.56 | −2.81 | −2.36 | −1.61 | −3.99 | −1.59 | −1.55 | −2.27 | −3.65 | −1.07 | −3.26 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 154 | 353 | 219 | 145 | 92.68 | 92.71 | 83.32 |
| Expenses | 140 | 286 | 205 | 135 | 94.20 | 92.15 | 85.60 |
| Operating Profit | 13.95 | 67.76 | 14.94 | 9.96 | −0.99 | 0.99 | −1.87 |
| OPM % | 9.0% | 19.0% | 7.0% | 7.0% | −1.6% | 0.8% | −2.2% |
| Other Income | 0.99 | 0.99 | 9.98 | −0.99 | 1.99 | 0.99 | 0.52 |
| Interest | 3.99 | 9.01 | 12.01 | 11.01 | 9.01 | 8.01 | 8.24 |
| Depreciation | 0.99 | 5.99 | 8.98 | 7.99 | 6.98 | 5.99 | 6.26 |
| Profit before tax | 9.99 | 54.02 | 3.01 | −11.01 | −16.01 | −12.99 | −15.85 |
| Tax % | 31.1% | 25.1% | 110.1% | −5.0% | −20.9% | −14.9% | — |
| Exceptional items | 0.00 | −0.09 | −0.09 | −1.57 | −0.46 | 0.00 | 0.00 |
| Net Profit | 7.01 | 40.04 | 0.00 | −9.99 | −12.01 | −11.01 | −13.32 |
| EPS (Rs) | 5.28 | 31.12 | −0.21 | −7.80 | −9.53 | −8.52 | −10.25 |
| Dividend payout % | 0.0% | 3.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 10.01 | 12.99 | 13.01 | 12.99 | 12.99 |
| Reserves | 72.75 | 72.80 | 62.74 | 50.83 | 39.84 |
| Borrowings | 77.03 | 70.98 | 72.99 | 83.07 | 78.99 |
| Other Liabilities | 130 | 119 | 91.95 | 81.72 | 76.82 |
| Total Liabilities | 290 | 276 | 241 | 230 | 209 |
| Fixed Assets | 93.36 | 88.32 | 58.23 | 57.24 | 51.15 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 197 | 187 | 182 | 171 | 157 |
| Inventories | 36.94 | 47.92 | 47.94 | 53.91 | 45.95 |
| Trade receivables | 102 | 83.31 | 73.28 | 67.29 | 68.30 |
| Cash & equivalents | 6.99 | 5.99 | 5.99 | 3.99 | 3.99 |
| Total Assets | 290 | 276 | 241 | 230 | 209 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 24.95 | 25.94 | −8.98 | 0.00 | 10.97 |
| Cash from investing activity | −43.89 | −8.98 | 19.98 | −1.99 | 0.99 |
| Cash from financing activity | 20.03 | −17.01 | −10.01 | 2.01 | −12.02 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 41.52 | 10.49 | 5.59 | 3.77 | 0.45 |
| Free cash flow | −17.04 | 16.03 | 9.02 | −4.01 | 11.02 |
| CFO / OP % | 36.9% | 201.9% | 38.9% | −272.1% | 1,558.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 105 | 138 | 184 | 262 | 267 |
| Inventory days | 58 | 117 | 182 | 330 | 278 |
| Days payable | 113 | 165 | 254 | 405 | 317 |
| Cash conversion cycle | 52 | 92 | 114 | 190 | 230 |
| Working capital days | 19 | 23 | 57 | 54 | −31 |
| ROCE % | — | 9.0% | 1.0% | −4.0% | −4.0% |
For the Jun 2026 quarter, ANG Lifesciences India reported sales of ₹15.25 Cr, down 37.8% year on year and net profit of −₹4.25 Cr. The operating margin was −12.8%.
ANG Lifesciences India's sales for the year to Mar 2026 were ₹92.71 Cr; over the last twelve months they were ₹83.32 Cr.
Net profit for the year to Mar 2026 was −₹11.01 Cr, and −₹13.32 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−10.25.
ANG Lifesciences India reported borrowings of ₹78.99 Cr at Mar 2026, against cash and equivalents of ₹3.99 Cr.
Cash from operations was ₹10.97 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹11.02 Cr.